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Developing clinical guidelines: a challenge to current
methods
Rosalind Raine, Colin Sanderson, Nick Black
Current methods for producing clinical guidelines are cumbersome and not always reliable. Could a
more streamlined approach improve coverage and make decisions more transparent?
Clinical guidelines are rarely based solely on research
evidence. In most cases they also incorporate the con-
sensus views of experts. Despite recognition of the
need for rigour in developing a consensus, current
approaches often lack sufficient transparency, fail to
make clear what influence the level of resources in the
health system has, lack sufficient reliability, and will
never achieve comprehensive and timely coverage of
the whole range of health care. We propose a new
approach that we believe will be more cost effective
and that could meet these challenges.
Need for consensus
Most professional societies and national agencies in
North America, Australia, and Europe recognise that
guidelines cannot be based on research evidence
alone. To paraphrase the philosopher David Hume:
“ought” statements such as guidelines cannot be
constructed from “is” statements such as research
evidence.1 The conversion from is to ought inevitably
introduces value judgments about underlying goals
and, in this context, somewhat subjective assessments
of the quality of the research evidence and its relevance
for particular patients and settings.
The recognised need to go beyond the often
limited research evidence has led to the use of expert
consensus in developing guidelines. The assumption is
that the views of a group have greater validity and reli-
ability than the judgment of an individual. In addition,
formal or structured methods for developing a
consensus have advantages over informal committees:
they should offer more transparent ways of synthesis-
ing individual judgments, can reduce the influence of
dominating personalities and “group think,” and can
provide valuable information on the extent and
reasons for differences of opinion.2
Since there can be no standard for checking the
validity of a consensus based guideline, we must ensure
that the way consensus is developed, in particular who
to involve and how to structure the process, is as rigor-
ous as possible. Despite rapid growth in the use of for-
mal methods for developing consensus throughout the
world,3 several challenges remain.4 5
Current approaches to developing
guidelines
The three commonly used methods for developing
guidelines are the nominal group technique, the
Delphi survey, and a hybrid of the two. In the nominal
group technique about 10 people are usually selected
to identify the questions to be covered in the guideline,
express their views in private, and then to discuss areas
of disagreement. After the discussion the participants
again provide their views in private, which the organis-
ers then analyse to derive the group view. These meet-
ings reduce the risk of misunderstandings and expose
the reasons for differences of opinion.6 In contrast, the
Delphi survey involves two or more rounds of postal
questionnaires. This allows larger and more geo-
graphically dispersed groups of participants and
avoids the risk of some individuals exercising undue
influence.7 However, the opportunities for clarification
and resolution of differences of opinion are more lim-
ited. A hybrid approach, pioneered by RAND, uses a
postal questionnaire for the first round of ratings and a
meeting for the second round.8
Formal, structured methods are used in England by
the National Institute for Health and Clinical
Excellence, which has a statutory role in producing
advice on best practice.9 These methods are also widely
used in other countries, with many of the guidelines
appearing on the website of the National Guideline
Clearinghouse (www.guideline.gov), an initiative of the
US Agency for Healthcare Research and Quality.
Methodological and practical concerns
These methods give rise to three main methodological
concerns and one practical concern. Firstly, the format,
although structured, is often not sufficient to allow the
reasons for judgments to be fully transparent. And only
some aspects of the process that influence the outcome
are made explicit (and even then not always). These
influences include the composition of the group (for
example, specialists tend to overstate the appropriate-
ness of the interventions they perform compared with
generalists10–13), whether a literature review was used,
and the procedure for aggregating judgments.
Our second concern is how the resource con-
straints faced in group members’ clinical work affect
their views. International differences in guidelines sug-
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gest that the level of resources available in a healthcare
system has an influence, along with cultural and
organisational factors.14 The few attempts that have
been made to examine such influences directly have
produced conflicting results.4 15 Until this issue has
been clarified, it is unwise to assume that contextual
issues, such as availability of resources, are ignored by
groups when making decisions or that a group’s view
about value and affordability of treatments coincides
with that of the wider community.16 17
The third concern is reliability, particularly for
nominal groups. Their strength lies in providing a
forum for detailed discussion, but it can also be their
weakness because it can lead to unrepresentative, and
therefore unreliable, judgments. Delphi surveys using
larger groups show greater within and between group
reliability (A Hutchings et al, unpublished data). A
trade-off is therefore needed between keeping a group
small enough to allow face to face discussions that
reveal people’s reasoning and large enough to ensure
reliable guidelines are produced.
Finally, we have a practical concern about the
sustainability of existing programmes to develop
guidelines given the time and cost involved. For exam-
ple, in England the National Institute for Health and
Clinical Excellence takes at least 18 months and
convenes as many as 15 meetings of the guideline
development groups to produce guidance that may
need to be reviewed every couple of years. The
producers of one guideline in Spain had to draft 13
versions of a data collection form and establish 10
working groups (www.guideline.gov). These processes
mean that only a small proportion of health care will
ever be covered and it may not be feasible to update
guidelines frequently enough.
Suggestions for a way forward
With these concerns in mind, we suggest some
improvements in the process for developing guide-
lines. Transparency could be enhanced by:
x Making the goals of each guideline explicit—for
example, effectiveness, cost effectiveness, equity
x Providing information on the reasons for disagree-
ments within a guideline development group—such as,
differences in interpretation of the research literature,
differences in personal experience, different percep-
tions of or responses to costs
x Publishing information on the closeness of agree-
ment about a recommendation as well as the strength
of support for a recommendation.
The influence of the resource constraints in the
local health system should be considered at an early
stage. Two useful steps would be to provide the
members of the group with authoritative information
about the costs of the treatments being considered and
to carry out an outcome valuation exercise to ensure
that the costs of any recommended treatments are not
greatly out of line with those in other guidelines and
broader societal views.
Reliability should be ensured by checking the views
of nominal groups against those of the wider commu-
nity. This could also help improve ownership of the
guidelines. Including clinicians in typical practice,
research methodologists, and patients in the process
might also improve reliability.
The practicality of creating and maintaining guide-
lines across the whole range of health care requires the
use of a more efficient means of guideline develop-
ment, with fewer group meetings and a shorter time
frame.
New approach
We propose three meetings of a guideline develop-
ment group comprising relevant practitioners and
other stakeholders. At the first meeting the group
would identify the specific issues to be examined.
Methodologists would then review and synthesise the
research evidence and other relevant material on
effectiveness, cost, and cost effectiveness, taking care to
document any judgments about conflicting evidence
and methodological limitations.18 The evidence and
stakeholders views would be used to develop and pilot
a questionnaire consisting of the relevant clinical
scenarios to be considered. Each scenario would be
accompanied by a Likert scale for participants to pro-
vide a rating from 1 (strongly disagree) to 9 (strongly
agree), with a separate box for don’t know.
Members of the guideline development group
would complete these questionnaires privately, and the
groups’ view would be presented at the second
meeting. The group would explore the extent of, and
reasons for, disagreements and clarify ambiguities. Par-
ticipants would then have an opportunity to revise
their ratings privately. The meeting would be observed
and audiotaped to enable a thematic analysis of the
extent to which issues such as cost, effectiveness, prior-
ity, feasibility, and acceptability influence ratings. For
example, it may be important to understand whether
the development group judged an intervention to be
appropriate in a particular instance because it
accepted a limited amount of evidence of a large ben-
efit or a wealth of evidence for a small benefit.
The second meeting should also consider the value
of the expected health outcomes. It is not yet clear what
approach would be feasible for routine use, but a first
step would be to report group members’ valuations
and how these affect their judgments. The representa-
tiveness of the groups’ ratings should be checked by
posting a random sample of the results to a large, simi-
larly composed group, who would be invited to rate the
results and to comment on the overall guidelines. The
development group would then meet for a third time
to turn their appropriateness ratings into recommen-
dations, having considered the results of the larger sur-
vey.
The published guidelines would include an indica-
tion of the underlying assumptions of the group and
the strength of support for each recommendation
together with the extent of agreement about it.
Surprising or controversial recommendations would
be explained.
The research evidence informing the guidelines
should be reviewed using the previously agreed search
strategy every two years. The guideline development
group should then meet to decide whether the guide-
lines should be reconsidered in the light of new
research evidence. In addition, the guideline develop-
ment group would meet if major new research
evidence is published in the interim.
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We believe such an approach would meet the prac-
tical challenges outlined above. We also contend that
the resulting guidelines would prove to be as valid and
reliable as those emanating from the existing
production methods and would be more cost effective.
This contention should be tested through a rigorous
comparison with currently used methods.
We thank John Cairns and Andrew Hutchings for advice and
comments on the drafts of this article.
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Summary points
The translation of research evidence into
guidelines has barely been considered
Formal consensus methods used to develop
guidelines lack sufficient transparency and
reliability, and the process is too cumbersome to
be sustainable
A new approach is suggested which makes the
goals, reasons for disagreement, and degree of
consensus explicit
Inclusion of a survey stage enhances reliability
Meetings of the development group are limited to
three to ensure sustainability
Chocolate poisoning
Readers may be intrigued to know that “man’s best friend” may
be at risk from one of our favourite treats—chocolate. The
potential hazards to humans of eating too much chocolate are
well known (obesity and dental caries to name but two), but you
may be unaware that chocolate is potentially lethal to dogs.
Chocolate is derived from the roasted seeds of the plant
Theobroma cacao, and the main toxic components are the
methylxanthine alkaloids theobromine and caffeine. Humans can
easily digest and excrete methylxanthines, the half life of
theobromine being 2-3 hours. However absorption in dogs is
slow, with metabolism in the liver and extrahepatic recirculation
before excretion in the urine. The half life of theobromine in
dogs is about 18 hours.
Theobromine primarily affects the central nervous system,
cardiovascular system, and respiratory system, as well as having a
diuretic effect. The first signs of poisoning in dogs include
vomiting, haematemesis, and polydipsia. Other signs may include
hyperexcitability, hyperirritability, tachycardia, excessive panting,
ataxia, and muscle twitching. Effects may progress to cardiac
arrhythmias, seizures, and death. Most symptoms will begin to
appear within two hours of ingestion, but, as theobromine is
metabolised slowly, it can take as long as 24 hours for them to
appear and up to three days for recovery. Although there is no
specific antidote, supportive management includes induction of
vomiting and administration of activated charcoal, oxygen, and
intravenous fluids.
The lethal dose of theobromine is reported to be 100-500 mg/kg
of body weight in dogs. However, not all types of chocolate
contain the same amount of theobromine: cocoa powder and
plain chocolate contain the highest concentrations (20 mg/g and
15 mg/g), milk chocolate has much less (2 mg/g), and white
chocolate has the lowest concentration (0.1 mg/g). Thus, less than
100 g of plain chocolate may be fatal for a 10 kg dog.
Although it is relatively safe to give your pet a small chocolate
treat occasionally, all dogs are potentially at risk from chocolate,
and the safer alternative is to give special “pet chocolate” that
does not contain theobromine (but can still cause obesity).
As a final thought, keen gardeners who like to spread mulch on
their garden in the spring and summer months should be aware
that cocoa shell mulch also contains very high levels of
theobromine (25 mg/g). As it has the characteristic chocolate
smell it may be attractive to dogs but is potentially lethal.
Remember, dogs love chocolate as much as we do—keep boxes
of chocolates, Easter eggs, and tins of cocoa out of paws’ reach.
Fiona Finlay consultant community paediatrician, Child Health
Department, Bath NHS House, Bath (fiona.finlay@banes-pct.nhs.uk),
Simon Guiton veterinary surgeon, 12 Raby Place, Bath
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